Table 3 Time to malignancy diagnosis in the study population

Head and neck

2.97 (1.81–4.75)

6.70 (3.96–7.94)

Lip

5.12 (5.12 5.12)

6.36 (4.91–7.81)

Digestive

 Esophagus

2.45 (0.57–4.79)

4.49 (3.97–6.30)

 Stomach

3.89 (2.23–5.19)

5.53 (2.93–7.41)

 Colon and rectum

3.87 (2.01–6.13)

4.26 (1.48–6.88)

 Anus

5.31 (5.10–5.52)

NA

 Liver

3.11 (1.31–4.63)

5.16 (2.25–7.52)

 Gallbladder and bile duct

3.97 (1.03–4.88)

4.21 (3.70–4.86)

 Pancreas

1.93 (0.68–4.50)

3.93 (2.94–8.53)

 Lung

3.99 (1.55–5.31)

5.19 (3.01–7.07)

Connective tissue and skin

 Bone and cartilage

2.92 (0.00–5.85)

4.38 (1.76–7.01)

 Melanoma

6.02 (2.82–9.03)

9.81 (3.51–9.82)

 Non-melanoma skin cancer

4.58 (2.88–6.95)

5.19 (3.22–7.11)

 Kaposi’s sarcoma

1.12 (0.84–1.80)

NA

Reproductive and genital tract

 Breast

2.63 (1.53–6.71)

5.47 (4.33–8.22)

 Uterine cervix

3.02 (1.42–5.41)

5.17 (1.45–7.00)

 Uterus

2.72 (0.65–3.72)

7.23 (4.04–7.88)

 Ovary

0.85 (0.51–4.03)

5.81 (1.93–7.85)

 Vulva, vagina

NA

5.23 (2.72–7.73)

 Prostate

2.95 (1.25–5.31)

4.05 (0.00–6.52)

 Testis

1.59 (0.41–2.49)

0.84 (0.84–0.84)

Urinary tract

 Kidney

1.10 (0.16–3.37)

4.82 (0.45–7.10)

 Bladder/urinary tract

3.00 (1.69–5.70)

3.73 (2.87–6.49)

 Brain

4.05 (1.56–4.13)

2.83 (1.78–4.25)

 Thyroid

2.32 (0.90–4.33)

5.15 (3.29–7.21)

Hematopoietic system

 Hodgkin’s lymphoma

1.22 (0.85–1.59)

5.40 (5.23–5.56)

 NHL

4.14 (1.54–5.68)

4.56 (2.47–7.78)

 Multiple myeloma

1.81 (0.93–1.96)

3.81 (1.20–6.51)

 Leukemia

3.30 (2.00–5.85)

4.73 (3.39–7.99)

 Unknown primary

3.87 (1.97–5.56)

4.39 (2.18–6.52)

 Total

2.94 (1.19–5.11)

4.96 (2.70–7.32)